CN101176711A - Yitarbisin sustained-release implantation agent for curing entity tumour - Google Patents
Yitarbisin sustained-release implantation agent for curing entity tumour Download PDFInfo
- Publication number
- CN101176711A CN101176711A CNA2007102028891A CN200710202889A CN101176711A CN 101176711 A CN101176711 A CN 101176711A CN A2007102028891 A CNA2007102028891 A CN A2007102028891A CN 200710202889 A CN200710202889 A CN 200710202889A CN 101176711 A CN101176711 A CN 101176711A
- Authority
- CN
- China
- Prior art keywords
- darubicin
- acid
- sustained
- cancer
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an idarubicin sustained-release implant capability for curing solid tumors, such as lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer, colon cancer and rectum cancer. The invention is characterized in that: the sustained-release implant comprises idarubicin, sustained-release excipient and a certain amount of sustained-release regulator; the sustained-release excipient is mainly one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate); the idarubicin can be released slowly into part of the tumor during the degradation and adsorption, significantly reducing the systemic toxicity and sustaining the effective medicine concentration simultaneously. The invention has the advantages that: the systemic toxicity of idarubicin can be significantly reduced; the effective medicine concentration can be improved selectively at part of the tumor; the invention can be applied to the prevention of tumor recurrence after operation and chemotherapy and combined therapy of various solid tumors and metastatic tumors that are not suitable for operation.
Description
(1) technical field
The present invention relates to a kind of Yitarbisin sustained-release implantation agent for the treatment of entity tumor, belong to technical field of pharmaceuticals.
(2) background technology
In the decades in past, though obtained bigger progress about the research of cancer, its mortality rate still occupies the prostatitis of the various common causes of the death.Up-to-date data show that China had 3,000,000 people to die from cancer in 2006.Because be subjected to the influence of environmental pollution and Bad Eating Habit, the sickness rate of cancer rises year by year and is rejuvenation trend.Have data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Estimate that the year two thousand twenty China will have 4,000,000 people to die from cancer every year.Therefore, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
The medicine that is used for treatment of cancer at present increases year by year, wherein, darubicin: 4-idarubicin (kind Victor, Idarubicin, Idamydn, Zavdos) be used to be grown up acute non-lymphoid leukemia, acute myeloid leukemia and children acute lymphoid leukemia are share with Ara-C, are better than daunorubicin.According to reach than the anthracene nucleus structure on the 4th do not have methoxyl group, thereby lipotropy is stronger than daunorubicin, the absorption efficiency of cell is also very fast.Chimeric according to reaching specific energy to DNA, thus it is synthetic to suppress RNA.Can also make cell rest on the G of cell cycle by suppressing the DNA topoisomerase II and produce free radical to make the DNA chain interruption
2Phase.Take place Drug resistance also than daunorubicin for lacking.According to reaching: 8～12mg/m than intravenous injection
2D slowly injected logotype 3 days in 10～15 minutes.When the coupling cytosine arabinoside, but add quiet notes cytosine arabinoside 25mg/m every day
2D, logotype 5 days.Though darubicin is united separately or with other anticarcinogen some tumor may be had certain effect by tool,, limited its clinical practice as bone marrow depression, potential cardiac toxicity and liver function toxicity by the caused whole body toxic and side effects of conventional route administration.
(3) summary of the invention
Based on above examination to prior art, the present invention compares other tumor, found that darubicin has comparatively significantly action effect to multiple entity tumor.Yet conventional method is difficult to bring into play its anti-tumor effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of entity tumor, not only effect is obvious, and its general toxicity obviously alleviates.
The present invention treats the sustained-release implant of entity tumor, it is characterized in that this sustained-release implant contains the darubicin of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) darubicin 0.1%-40%
(2) slow-release auxiliary material 60%-99%
(3) slow release regulator 0-15%
Wherein darubicin can be its various salt, preferred salt hydrochlorate.The percentage by weight of darubicin in sustained-release implant decide because of specifically needing, 1% to 30% serving as preferably, with 5%-20% for most preferably.
Decanedioic acid (SA) copolymer), a kind of or its combination among poly-(L-lactide-co-etherophosphoric acid) (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)) slow-release auxiliary material of the present invention mainly is selected from the copolymer (PLGA), polifeprosan of polylactic acid (PLA), glycolic and hydroxyacetic acid (to carboxy phenyl propane (p-CPP):.
Wherein the molecular weight peak value of polylactic acid (PLA) is 5000-15000,10000-20000,20000-35000 or 30000-50000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
The molecular weight peak value of the copolymer of glycolic and hydroxyacetic acid (PLGA) is 5000-15000,15000-35000,35000-45000 or 45000-80000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 150003-5000 for most preferably.The percentage by weight of glycolic and hydroxyacetic acid is 90: 10,80: 20, and 70: 30,60: 40,50: 50 or 40: 60; Wherein with 80: 20,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.
Polifeprosan (to carboxy phenyl propane (p-CPP): the percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) decanedioic acid (SA) copolymer) is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40; Wherein with 80: 20,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.
The molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 5000-15000,10000-20000,20000-35000 or 30000-50000, serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
In " slow-release auxiliary material complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor), slow-release auxiliary material is had a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some slow-release auxiliary material.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above slow-release auxiliary material has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned slow-release auxiliary material, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.Serve as preferred wherein with mannitol, sorbitol.
Characteristics of the present invention are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other slow-release auxiliary material.The slow-release auxiliary material of adding is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Slow-release auxiliary material also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned slow-release auxiliary material is applicable to the compositions that contains or do not contain additive.
The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.1-500 milligram/patient, is ideal with 10-300 milligram/patient, with 20-200 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of compositions can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.
Each component and the weight percentage in compositions thereof are preferred one of following in the sustained-release implant:
(A) polylactic acid of the darubicin of 1%-5% and 95%-99%;
(B) polylactic acid of the darubicin of 5%-10% and 90%-95%;
(C) polylactic acid of the darubicin of 10%-15% and 85%-90%;
(D) polylactic acid of the darubicin of 15%-25% and 75%-85%;
(E) polylactic acid of the darubicin of 25%-40% and 60%-75%;
(F) copolymer of the glycolic of the darubicin of 1%-10% and 90%-99% and hydroxyacetic acid;
(G) copolymer of the glycolic of the darubicin of 10%-20% and 80%-90% and hydroxyacetic acid;
(H) copolymer of the glycolic of the darubicin of 20%-30% and 70%-80% and hydroxyacetic acid;
(I) copolymer of the glycolic of the darubicin of 30%-40% and 60%-70% and hydroxyacetic acid;
(J) polifeprosan of the darubicin of 5%-15% and 85%-95%;
(K) polifeprosan of the darubicin of 15%-35% and 65%-85%;
(L) 5% darubicin and 95% poly-(L-lactide-co-etherophosphoric acid);
(M) 10% darubicin and 90% poly-(L-lactide-co-etherophosphoric acid);
(N) 20% darubicin and 80% poly-(L-lactide-co-etherophosphoric acid);
(O) 30% darubicin and 70% poly-(L-lactide-co-etherophosphoric acid);
(P) 5% darubicin and 95% poly-(L-lactide-co-phosphoric acid propyl ester);
(Q) 10% darubicin and 90% poly-(L-lactide-co-phosphoric acid propyl ester);
(R) 20% darubicin and 80% poly-(L-lactide-co-phosphoric acid propyl ester);
(S) 30% darubicin and 70% poly-(L-lactide-co-phosphoric acid propyl ester).
Each component and the weight percentage in compositions thereof are one of further preferred following in the sustained-release implant:
(A) mannitol of the polylactic acid of the darubicin of 1%-5% and 85%-98% and 0.5%-15%;
(B) sorbitol of the polylactic acid of the darubicin of 5%-10% and 90%-95% and 0.5%-10%;
(C) sodium chloride of the polylactic acid of the darubicin of 10%-15% and 85%-90% and 0.5%-10%;
(D) mannitol of the polylactic acid of the darubicin of 15%-25% and 75%-85% and 0.25%-5%;
(E) sorbitol of the polylactic acid 0.1%-8% of the darubicin of 25%-40% and 60%-75%;
(F) mannitol of the copolymer of the glycolic of the darubicin of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(G) sorbitol of the copolymer of the glycolic of the darubicin of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(H) sodium chloride of the copolymer of the glycolic of the darubicin of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(I) mannitol of the copolymer of the glycolic of the darubicin of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
(J) mannitol of the polifeprosan of the darubicin of 5%-15% and 85%-95% and 1%-5%;
(K) mannitol of the polifeprosan of the darubicin of 15%-35% and 65%-85% and 0.25%-7.5%;
(L) 5% darubicin and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(M) 10% darubicin and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(N) 20% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(O) 30% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(P) 5% darubicin and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(Q) 10% darubicin and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(R) 20% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(S) 30% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.
Sustained-release implant is used for the treatment of entity tumor, comprise the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and come from gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes, former or cancer, sarcoma or the carcinosarcoma of secondary.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Because anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, said composition can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer composition of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Test one, darubicin are to the inhibitory action of growth of tumour cell.
Be the inhibitory action of checking darubicin to other growth of tumour cell, this test is added to darubicin (15ug/ml) in 24 hours the various tumor cells of In vitro culture (table 1), continue to cultivate after 48 hours the counting cells sum and calculates its suppression ratio to growth of tumour cell (%).
The suppression ratio of growth of tumour cell (%)=((cellular control unit is counted the test group cell number)/cellular control unit number) * 100%
Table 1
The result of test one shows that compare with matched group, darubicin all has obvious inhibitory action (P＜0.05) to the examination growth of tumor, and is wherein right.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of entity tumor provides new selection.
The sustained-release implant that contains darubicin can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing of implanting.
The preparation method of sustained-release implant of the present invention is as follows:
1, the slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
2, adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement.
3, remove organic solvent.Vacuum drying or cold drying all can.
4, dried solid composite is made different shape as required.
5, ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
(4) specific embodiment
Embodiment one,
The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) of (90mg) of will weighing is put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 10 milligrams of darubicins, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% darubicin.The drug release time of this sustained-release implant in external normal saline is 20-28 days, is 24-30 days at the subcutaneous drug release time of mice.
Embodiment two
Make sustained-release implant by embodiment one described method, but contained anticancer effective component is one of following:
(A) 1% darubicin and and 99% polylactic acid;
(B) 5% darubicin and and 95% polylactic acid;
(C) 10% darubicin and 90% polylactic acid;
(D) 15% darubicin and 85% polylactic acid;
(E) 20% darubicin and 80% polylactic acid.
Embodiment three
(molecular weight is the PLGA of 15000-25000 to the slow-release auxiliary material of (80mg) of will weighing, 50: 50) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add the 20mg darubicin, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 20% darubicin.The drug release time of this sustained-release implant in external normal saline is 25-32 days, is 25-34 days at the subcutaneous drug release time of mice.
Embodiment four
Make sustained-release implant by embodiment three described methods, contained anticancer effective component that different is is one of following:
(1) copolymer of the glycolic of the darubicin of 1%-10% and 90%-99% and hydroxyacetic acid;
(2) copolymer of the glycolic of the darubicin of 10%-20% and 80%-90% and hydroxyacetic acid;
(3) copolymer of the glycolic of the darubicin of 20%-30% and 70%-80% and hydroxyacetic acid;
(4) copolymer of the glycolic of the darubicin of 30%-40% and 60%-70% and hydroxyacetic acid;
The copolymer of (5) 5% darubicin and 95% glycolic and hydroxyacetic acid;
The copolymer of (6) 10% darubicin and 90% glycolic and hydroxyacetic acid;
The copolymer of (7) 20% darubicin and 80% glycolic and hydroxyacetic acid;
The copolymer of (8) 30% darubicin and 70% glycolic and hydroxyacetic acid.
Embodiment five
(molecular weight is the PLGA of 20000-40000 to the slow-release auxiliary material of (85mg) of will weighing, 75: 25) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add 10mg darubicin and 5mg mannitol, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% darubicin.The drug release time of this sustained-release implant in external normal saline is 26-28 days, is 26-28 days at the subcutaneous drug release time of mice.
Embodiment six
Make sustained-release implant by embodiment five described methods, contained anticancer effective component that different is is one of following:
(1) mannitol of the copolymer of the glycolic of the darubicin of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(2) sorbitol of the copolymer of the glycolic of the darubicin of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%1-0%;
(3) sodium chloride of the copolymer of the glycolic of the darubicin of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(4) mannitol of the copolymer of the glycolic of the darubicin of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
The copolymer of (5) 5% darubicin and 92% glycolic and hydroxyacetic acid and 2% sodium chloride;
The copolymer of (6) 10% darubicin and 85% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (7) 20% darubicin and 75% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (8) 30% darubicin and 75% glycolic and hydroxyacetic acid and 5% mannitol.
Embodiment seven
95mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 50: 50) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 5mg darubicin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 5% Yitarbisin sustained-release implantation agent.The drug release time of this sustained-release implant in external normal saline is 10-16 days, is 12-14 days at the subcutaneous drug release time of mice.
Embodiment eight
Make sustained-release implant by embodiment seven described methods, that contained anticancer effective component is is one of following but different is:
(1) polifeprosan of the darubicin of 1%-15% and 85%-95%;
(2) polifeprosan of the darubicin of 15%-35% and 65%-85%;
(3) 5% darubicin and 95% polifeprosan;
(4) 10% darubicin and 90% polifeprosan;
(5) 15% darubicin and the polifeprosan of 85%-95%;
(6) 20% darubicin and 80% polifeprosan.
Embodiment nine
90mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 30: 70) and 5mg sodium chloride are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 5mg darubicin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 5% Yitarbisin sustained-release implantation agent.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is 12-16 days at the subcutaneous drug release time of mice.
Embodiment ten
Make sustained-release implant by embodiment ten described methods, that contained anticancer effective component is is one of following but different is:
(1) mannitol of the polifeprosan of the darubicin of 5%-15% and 85%-95% and 1%-5%; Or
(2) mannitol of the polifeprosan of the darubicin of 15%-35% and 65%-85% and 0.25%-7.5%.
Embodiment 11
85mg slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) and 10mg mannitol are put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of darubicins, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% darubicin.The drug release time of this sustained-release implant in external normal saline is 22-24 days, is 24-28 days at the subcutaneous drug release time of mice.
Embodiment 12
Make sustained-release implant by embodiment 11 described methods, used slow-release auxiliary material is selected from one of following or its combination:
(A) 1% darubicin and and 95% polylactic acid and 4% mannitol;
(B) 5% darubicin and and 93% polylactic acid and 2% mannitol;
(C) 10% darubicin and 85% polylactic acid and 5% mannitol;
(D) 15% darubicin and 82% polylactic acid and 3% sodium chloride;
(E) 20% darubicin and 78% polylactic acid and 2% sodium chloride.
Embodiment 13
Make sustained-release implant by embodiment 1 to 11 described method, used slow-release auxiliary material is selected from one of following or its combination:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,15000-35000,35000-45000 or 45000-80000 and the copolymer of hydroxyacetic acid (PLGA);
C) polifeprosan is (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer), be 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to the percentage by weight of carboxy phenyl propane (p-CPP) and decanedioic acid (SA);
On the basis of above-mentioned slow release, the present invention finds that further body is implanted into darubicin other entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, skin carcinoma, lymphoma, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are also had good therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.Following in vivo test is used for explanation but not limitation of the present invention.
Embodiment 14
With 70,80,90 and 95mg molecular weight peak value be that the p (LAEG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg darubicin respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% darubicin again.The drug release time of this slow releasing agent in external normal saline is 28-36 days, is about 28-38 days at the subcutaneous drug release time of mice.
Embodiment 15
The method step that is processed into sustained-release implant is identical with embodiment 14, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% darubicin;
(2) 5%-10% darubicin;
(3) 10%-20% darubicin;
(4) 20%-40% darubicin;
The sodium chloride of (5) 5% darubicin and 92% p (LAEG-EOP) and 2%;
The mannitol of (6) 10% darubicin and 85% p (LAEG-EOP) and 5%;
The mannitol of (7) 20% darubicin and 75% p (LAEG-EOP) and 5%;
The mannitol of (8) 30% darubicin and 75% p (LAEG-EOP) and 5%.
Embodiment 16
With 70,80,90 and 95mg molecular weight peak value be that the p (DAPG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg darubicin respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% darubicin again.The drug release time of this slow releasing agent in external normal saline is 36-42 days, is about 38-44 days at the subcutaneous drug release time of mice.
Embodiment 17
The method step that is processed into sustained-release implant is identical with embodiment 16, but the molecular weight peak value of different is p (DAPG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% darubicin;
(2) 5%-10% darubicin;
(3) 10%-20% darubicin;
(4) 20%-40% darubicin;
The sodium chloride of (5) 5% darubicin and 92% p (DAPG-EOP) and 2%;
The mannitol of (6) 10% darubicin and 85% p (DAPG-EOP) and 5%;
The mannitol of (7) 20% darubicin and 75% p (DAPG-EOP) and 5%;
The mannitol of (8) 30% darubicin and 75% p (DAPG-EOP) and 5%.
Embodiment 18, tumor are implanted into the inhibitory action of darubicin to entity tumor
Tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, when tumor growth during to 1.0cm left and right sides diameter (inoculation back the 8th day), animal is divided into 7 groups at random, 5 every group.Be normal saline group, darubicin lumbar injection group (hereinafter to be referred as darubicin abdominal cavity group), darubicin local injection group (being called for short the darubicin partial groups), high molecular polymer group (being called for short high poly-group), Yitarbisin sustained-release implantation agent group with (5% group, 10% group of the made sustained-release implant of embodiment four, with 20% group, be called for short implant 5%, implant 10%, implant 20%).With 70% alcohol disinfecting tumor surface skin, selection is apart from tumor lower edge 1cm place, cut off the long otch of 1mm, with puncture needle with in the darubicin implant implantation tumour tissue, not pastille high molecular polymer, darubicin implant 5%, darubicin implant 10%, darubicin implant 20%.Sew up the incision and prevent that implant from spilling.6 weeks were put to death animals after the implant embedding with vernier caliper measurement tumor size in per 3 days, and the back of weighing is complete peels off tumor and claim tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 19 tumors are implanted into the tumor-inhibiting action of darubicin spit of fland sustained-release implant to mice lung cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent according to embodiment 18 described methods and step to mice lung cancer.Used implant adjuvant is PLGA (molecular weight is 15000-30000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50), is derived from embodiment four.The darubicin implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 60%, 72%, 86%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments: tumor control rate is respectively 56%, 68%, 84%, compares with the local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and darubicin local injection group and normal saline group comparison of tumor suppression ratio are 14% and 12%, and repeated experiments: tumor control rate is 18% and 13%.The tumour inhibiting rate of darubicin implant obviously surpasses darubicin lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to mouse breast cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to mouse breast cancer according to embodiment 18 described methods and step, used implant is from embodiment one.Experimental result shows that the tumor control rate of 1%, 10% and 25% darubicin implant is respectively 52%, 72%, 84%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 52%, 76%, 86%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 14%, and repeated experiments: tumor control rate is 13% and 10%.The tumour inhibiting rate of darubicin implant obviously surpasses darubicin lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 21 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mouse ovarian cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent according to embodiment 18 described methods and step to the mouse ovarian cancer, used implant is 5%, 10% and 20% polifeprosan (percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) is 50: 50), from embodiment eight.The darubicin implant of experimental result proof various dose is implanted in the mouse ovarian cancer and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 48%, 70%, 80%, compares with darubicin local injection group, and low dose group P value equals 0.001, and middle and high dosage group P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 40%, 66%, 84%, compares with darubicin local injection group, and low dose group P value is less than 0.05, and middle and high dosage group P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and darubicin local injection group and normal saline group comparison of tumor suppression ratio are 18% and 22%, and repeated experiments: tumor control rate is 25% and 16%.The tumour inhibiting rate of darubicin implant obviously surpasses darubicin lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 22 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice esophageal carcinoma
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice esophageal carcinoma according to embodiment 18 described methods and step, used implant is selected from embodiment six.The darubicin implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 48%, 68%, 84%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments finds that tumor control rate is respectively 56%, 72%, 82%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 16%, and repeated experiments shows that tumor control rate is 14% and 10%.The tumour inhibiting rate of darubicin implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 23 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to mouse pancreas cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to mouse pancreas cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of darubicin in sustained-release implant be 2.5%, 7.5% and the darubicin implant of 12.5%. experimental result proof various dose implant in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 40%, 56%, 76%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 48%, 62%, 78%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 14%.Repeated experiments finds that tumor control rate is 10% and 14%.The tumour inhibiting rate of darubicin implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 24 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice rectal cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice rectal cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of darubicin in sustained-release implant is 7.5%, 15% and 25%.The darubicin implant of experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 50%, 72%, 86%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 68%, 84%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 18%.Repeated experiments finds that tumor control rate is 12% and 10%.The tumour inhibiting rate of darubicin implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 25 tumors are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice carcinoma of prostate
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to the mice carcinoma of prostate according to embodiment 18 described methods and step, used implant adjuvant is p (LAEG-EOP) (molecular weight is 10000-25000).The content of darubicin in sustained-release implant is 5%, 10% and 20% (from embodiment 14).The darubicin implant of experimental result proof various dose is implanted in the nude mice model human prostata cancer entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 52%, 74%, 86%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 42%, 68%, 78%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 18%.Repeated experiments finds that tumor control rate is 12% and 14%.The tumour inhibiting rate of darubicin implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
Embodiment 26, tumor are implanted into the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to rat liver cancer
Check the tumor-inhibiting action of Yitarbisin sustained-release implantation agent to rat liver cancer according to embodiment 18 described methods and step, used implant adjuvant is p (DAPG-EOP) (molecular weight is 10000-25000).The content of darubicin in sustained-release implant is 5%, 10% and 20% (from embodiment 16).The content of darubicin in sustained-release implant is the darubicin implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Darubicin implant tumor control rate is respectively 52%, 70%, 88%, compares with darubicin local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 58%, 68%, 84%, compares with darubicin local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Darubicin lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 16% and 12%.Repeated experiments finds that tumor control rate is 8% and 10%.The tumour inhibiting rate of darubicin implant obviously surpasses lumbar injection group and local injection group, and its toxic reaction obviously alleviates, twice experimental result good reproducibility.
In addition, tumor is implanted into Yitarbisin sustained-release implantation agent other entity tumors such as gastric cancer, bladder cancer, carcinoma of testis, colon cancer, carcinoma of endometrium, lymphoma, the cerebral tumor, cervical cancer, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses darubicin lumbar injection group and local injection group.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
Claims (10)
1. a Yitarbisin sustained-release implantation agent for the treatment of entity tumor is characterized in that this sustained-release implant contains the darubicin of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, wherein,
The percentage by weight of darubicin in sustained-release implant is 0.1%-40%;
Slow-release auxiliary material is selected from a kind of or its combination in the copolymer, polifeprosan of polylactic acid, polyglycolic acid and hydroxyacetic acid, poly-(L-lactide-co-etherophosphoric acid), poly-(the L-lactide-co-phosphoric acid propyl ester);
The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin; Its percentage by weight in sustained-release implant is 0-15%.
2. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% darubicin and and 99% polylactic acid;
(B) 5% darubicin and and 95% polylactic acid;
(C) 10% darubicin and 90% polylactic acid;
(D) 15% darubicin and 85% polylactic acid;
(E) 20% darubicin and 80% polylactic acid;
(F) 5% darubicin and 95% glycolic and the copolymer of hydroxyacetic acid;
(G) 10% darubicin and 90% glycolic and the copolymer of hydroxyacetic acid;
(H) 20% darubicin and 80% glycolic and the copolymer of hydroxyacetic acid;
(I) 30% darubicin and 70% glycolic and the copolymer of hydroxyacetic acid;
(J) 5% darubicin and 95% polifeprosan;
(K) 15% darubicin and 85% polifeprosan;
(L) 5% darubicin and 95% poly-(L-lactide-co-etherophosphoric acid);
(M) 10% darubicin and 90% poly-(L-lactide-co-etherophosphoric acid);
(N) 20% darubicin and 80% poly-(L-lactide-co-etherophosphoric acid);
(O) 30% darubicin and 70% poly-(L-lactide-co-etherophosphoric acid);
(P) 5% darubicin and 95% poly-(L-lactide-co-phosphoric acid propyl ester);
(Q) 10% darubicin and 90% poly-(L-lactide-co-phosphoric acid propyl ester);
(R) 20% darubicin and 80% poly-(L-lactide-co-phosphoric acid propyl ester);
(S) 30% darubicin and 70% poly-(L-lactide-co-phosphoric acid propyl ester).
3. the sustained-release implant according to claim 1 is characterized in that the slow release regulator of this sustained-release implant is selected from xylitol, oligosaccharide, chitin, potassium chloride, sodium chloride, mannitol, sorbitol, hyaluronic acid, collagen protein or chrondroitin.
4. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% darubicin and and 95% polylactic acid and 4% mannitol;
(B) 5% darubicin and and 93% polylactic acid and 2% mannitol;
(C) 10% darubicin and 85% polylactic acid and 5% mannitol;
(D) 15% darubicin and 82% polylactic acid and 3% sodium chloride;
(E) 20% darubicin and 78% polylactic acid and 2% sodium chloride;
(F) 5% darubicin and 92% glycolic and the copolymer of hydroxyacetic acid and 2% sodium chloride;
(G) 10% darubicin and 85% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(H) 20% darubicin and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(I) 30% darubicin and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(J) 5% darubicin and 92.5% polifeprosan and 2.5% mannitol;
(K) 15% darubicin and 75% polifeprosan and 10% mannitol;
(L) 5% darubicin and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(M) 10% darubicin and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(N) 20% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(O) 30% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(P) 5% darubicin and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(Q) 10% darubicin and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(R) 20% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(S) 30% darubicin and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.
5. according to the described anti-cancer sustained-released implantation agent of claim 1-4, the molecular weight peak value that it is characterized in that polylactic acid is 5000-15000,10000-20000,20000-35000 or 30000-50000.
6. according to the described anti-cancer sustained-released implantation agent of claim 1-4, the molecular weight peak value that it is characterized in that the copolymer of glycolic and hydroxyacetic acid is 5000-15000,15000-35000,35000-45000 or 45000-80000.
7. according to the described anti-cancer sustained-released implantation agent of claim 1-4, it is characterized in that in the copolymer of glycolic and hydroxyacetic acid that the percentage by weight of glycolic and hydroxyacetic acid is 90: 10,80: 20,70: 30,60: 40,50: 50 or 40: 60.
8. according to the described anti-cancer sustained-released implantation agent of claim 1-4, it is characterized in that the percentage by weight to carboxy phenyl propane and decanedioic acid is 10: 90 in the polifeprosan (to carboxy phenyl propane-decanedioic acid copolymer), 20: 80,30: 70,40: 60,50: 50 or 60: 40.
9. the described sustained-release implant of claim 1-3 is characterized in that this sustained-release implant is in the tumor or the slow releasing injection and the solid sustained-release implant of all injections of tumor or placement.
10. the sustained-release implant according to claim 1 is characterized in that described sustained-release implant is used for the preparation treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and originate from gallbladder, the oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, former or the cancer of secondary of eyes, the pharmaceutical preparation of sarcoma or carcinosarcoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102028891A CN101176711A (en) | 2007-12-06 | 2007-12-06 | Yitarbisin sustained-release implantation agent for curing entity tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102028891A CN101176711A (en) | 2007-12-06 | 2007-12-06 | Yitarbisin sustained-release implantation agent for curing entity tumour |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101176711A true CN101176711A (en) | 2008-05-14 |
Family
ID=39403232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007102028891A Pending CN101176711A (en) | 2007-12-06 | 2007-12-06 | Yitarbisin sustained-release implantation agent for curing entity tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101176711A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013026454A1 (en) * | 2011-08-22 | 2013-02-28 | Valderm Aps | Treatment of clinical conditions with anthracyclines |
-
2007
- 2007-12-06 CN CNA2007102028891A patent/CN101176711A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013026454A1 (en) * | 2011-08-22 | 2013-02-28 | Valderm Aps | Treatment of clinical conditions with anthracyclines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN100563645C (en) | A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor | |
| CN101176713A (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN101176711A (en) | Yitarbisin sustained-release implantation agent for curing entity tumour | |
| CN101176716A (en) | Sunitinib sustained-release implantation agent for curing entity tumour | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
| CN101204368A (en) | Pirarubicin sustained-release implant treating for solid tumor | |
| CN101181231B (en) | Sustained-release implantation agent of urotrotiken | |
| CN100531712C (en) | Dasatini sustained-release implants for treating entity tumor | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour | |
| CN100531711C (en) | Erlotinib sustained-release implants for treating entity tumor | |
| CN101176715A (en) | Gefitinib sustained-release implantation agent for curing entity tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080514 |